Beyond glycated haemoglobin: Modelling contemporary management of type 2 diabetes with the updated Cardiff model.

ABSTRACT:

Aims

Recommendations on the use of newer type 2 diabetes (T2D) treatments (e.g., SGLT2 inhibitors and GLP-1 receptor agonists [RA]) in contemporary clinical guidelines necessitate a change in how T2D models approach therapy selection and escalation. Dynamic, person-centric clinical decision-making considers factors beyond a patient's HbA1c and glycaemic targets, including cardiovascular (CV) risk, comorbidities and bodyweight. This study aimed to update the existing Cardiff T2D health economic model to reflect modern T2D management and to remain fit-for-purpose in supporting decision-making.

Materials and methods

The Cardiff T2D model's therapy selection/escalation module was updated from a conventional, glucose-centric to a holistic approach. Risk factor progression equatio

SUBMITTER: McEwan P 

PROVIDER: S-EPMC11885066 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature